Pfizer off-patent division to merge with Mylan

29-07-2019

Rory O'Neill

Pfizer off-patent division to merge with Mylan

photobyphm / Shutterstock.com

Pfizer is to merge its off-patent drug business Upjohn with Mylan, in a deal that will see Pfizer shareholders own 57% of the new company.


Pfizer, Mylan, Upjohn, merger, viagra, celebrex, lipitor, Epipen, Array BioPharma, Scott Gottlieb

LSIPR